A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia

Exclusion Criteria

• •Impaired liver function (ALT and/or AST \> 2 x upper limit of normal range, or TBIL≥1.5 x upper limit of normal range);
• •Impaired renal function(Serum Creatinine \>176μmoL/L), or undergoing dialysis within 28 days before surgery;
• •Patients at high risk for bleeding, including congenital hemorrhagic disease(such as Hemophilia), Thrombocytopenia(CBC PLT\<30×109/L), Qualitative Plateletdefects(such as ITP, DIC, congenital abonormal platelet), or clinically significant active bleeding;
• •Hypertensive patients not achieving satisfactory BP control under hypertensive medication(Sitting SBP≥160mm Hg, and/or DBP≥105mm Hg during screen period);
• •Sitting SBP≤90mm Hg during screening period;
• •Diabetic Patients not achieving satisfactory blood glucose control(FBG≥11.1moL/L during screening period);
• •Known history of bronchial asthma, pulmonary heart disease or heart failure;
• •Participation in other trials within 30 days;
• •Pregnant women or women in lactation;